Full Press Release Details
Shareholders Vote in Favour of All Resolutions at its Annual General
DUBLIN--(BUSINESS WIRE)--July 30, 2014--ICON plc, (NASDAQ:ICLR),
a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries, today
announced that all resolutions at the Annual General Meeting of the
Company (AGM) held on July 29, 2014 (which resolutions had all been
recommended by the Board) were all duly passed by shareholders. These
resolutions were set out in the Notice of the AGM sent to shareholders
dated June 19, 2014 and are available on the ICON plc website.
The resolutions were all passed and the final results of proxy voting
| RESOLUTION NUMBER | RESOLUTION | TOTAL NUMBER OF VOTES | VOTE FOR | VOTE AGAINST | VOTE WITHHELD | |||||||||||
| 1.1 | To re-elect Dr. John Climax | 37,892,609 | 37,696,147 | 61,342 | 135,120 | |||||||||||
| 1.2 | To re-elect Prof. Dermot Kelleher | 37,892,609 | 30,919,648 | 6,821,493 | 151,468 | |||||||||||
| 1.3 | To re-elect Ms. Mary Pendergast | 37,892,609 | 37,742,171 | 15,568 | 134,870 | |||||||||||
| 1.4 | To re-elect Dr. Hugh Brady | 37,892,609 | 37,744,531 | 12,859 | 135,219 | |||||||||||
| 2 | To receive accounts and reports | 37,892,609 | 37,792,507 | 19,961 | 80,141 | |||||||||||
| 3 | To authorise the fixing of the auditors' remuneration | 37,892,609 | 36,078,675 | 1,730,318 | 83,616 | |||||||||||
| 4** | To authorise the Company to make market purchases of shares | 37,892,609 | 37,082,797 | 11,549 | 798,263 | |||||||||||
| 5** | To authorise the price range at which the Company can reissue shares it holds as treasury shares | 37,892,609 | 37,726,183 | 27,040 | 139,386 |
** Special Resolution. All resolutions are ordinary resolutions unless
This press release may contain forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 83 locations in 38 countries and has
approximately 11,000 employees. Further information is available at www.iconplc.com.
Brennan, Chief Financial Officer
Holmes, EVP Investor Relations and Corporate Development